Retatrutide in Black / African Ancestry Patients: Documented Efficacy Gaps and Pharmacogenomic Considerations

What Is Retatrutide and Why Does Ancestry Matter?

Retatrutide (LY3437943) activates three incretin and metabolic hormone receptors simultaneously: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This triple mechanism produced the largest weight reductions reported for any anti-obesity medication in a randomized controlled trial at the time of its Phase 2 publication [1]. The question of whether those results translate equally across racial and ethnic groups remains open.

The Representation Problem

In the Phase 2 trial by Jastreboff et al. (N=338), approximately 86% of participants were White, and only about 4% were Black or African American [1]. That sample size (roughly 14 individuals) cannot power any meaningful subgroup analysis. The U.S. Food and Drug Administration has repeatedly called for greater diversity in obesity drug trials, noting that enrollment demographics rarely match the populations most affected by the disease [2].

Why Black / African Ancestry Populations Need Specific Data

Non-Hispanic Black adults carry the highest age-adjusted obesity prevalence in the United States at 49.9%, compared with 41.4% among non-Hispanic White adults, according to 2021-2023 NHANES data from the CDC [3]. Black Americans also face disproportionate rates of type 2 diabetes, hypertension, and chronic kidney disease (CKD), all conditions where body-weight reduction could modify risk [4]. Without race-stratified trial data, clinicians prescribing retatrutide to Black patients must extrapolate from a study population that does not reflect them.

Phase 2 Efficacy: What the Trial Showed (and Did Not Show)

The 48-week Phase 2 dose-ranging study randomized 338 adults with obesity (BMI ≥30 kg/m², or ≥27 with at least one weight-related comorbidity) to one of six retatrutide dose groups or placebo [1]. Results were striking across all active arms.

Headline Weight-Loss Figures

Participants receiving the highest dose (12 mg weekly) lost a mean of 24.2% of body weight at 48 weeks, versus 2.1% in the placebo group. The 8 mg dose produced 22.8% weight loss, and the 4 mg maintenance dose yielded 17.0% [1]. These figures surpassed tirzepatide's SURMOUNT-1 results (22.5% at 72 weeks with 15 mg) [5] and semaglutide 2.4 mg from STEP-1 (14.9% at 68 weeks) [6].

The Missing Subgroup Analysis

The published Phase 2 manuscript and its supplementary appendix report subgroup analyses by sex, baseline BMI category, and presence of prediabetes. Race and ethnicity subgroups do not appear. This is not unusual for Phase 2 dose-finding studies with small sample sizes, but it means the evidence base for Black patients is functionally zero from a controlled-trial standpoint.

Comparator Context from Other GLP-1 Receptor Agonists

Some perspective can be drawn from larger GLP-1RA trials. In STEP-1 (semaglutide 2.4 mg), approximately 10.5% of participants were Black, and the FDA label does not report race-specific efficacy differences [6]. Tirzepatide's SURMOUNT-1 enrolled about 4.5% Black participants, again without published race-stratified outcomes [5]. A pattern emerges: the drugs producing the most significant weight loss have enrolled the fewest Black participants relative to disease burden.

Pharmacogenomic Factors That Could Influence Retatrutide Response

Retatrutide's triple-receptor mechanism introduces three distinct pharmacogenomic axes. Genetic variation in any of the three receptor genes (GIPR, GLP1R, GCG/GCGR) could modify drug response.

GLP-1 Receptor Variants

The GLP1R gene contains several coding variants with known functional effects. The rs10305420 variant (Pro7Leu) has a minor allele frequency of roughly 6-7% in African-descent populations compared to about 4% in European-descent populations, based on gnomAD data [7]. A 2021 pharmacogenomic study published in Diabetes linked GLP1R variants to differential glycemic response to liraglutide, though weight-loss endpoints were not the primary outcome [8].

GIP Receptor Polymorphisms

The GIPR Glu354Gln variant (rs1800437) shows different allele frequencies across populations cataloged in PharmGKB, with the Gln354 allele appearing in approximately 18-20% of European-ancestry individuals but at a lower frequency (about 8-10%) in African-ancestry populations [9]. This variant has been linked to reduced GIP-stimulated insulin secretion. Whether it modifies weight-loss response to a GIP receptor agonist has not been tested directly.

Glucagon Receptor Considerations

The glucagon receptor (GCGR) component of retatrutide adds another pharmacogenomic layer. A missense variant in GCGR (rs1801483, Gly40Ser) shows ancestry-dependent frequency patterns [7]. Glucagon signaling affects hepatic glucose output, energy expenditure, and amino acid metabolism. Population-level differences in GCGR signaling could theoretically widen or narrow the efficacy seen with the glucagon-agonist arm of retatrutide, but no clinical pharmacogenomic study has examined this in the context of triple-agonist therapy.

What Pharmacogenomics Cannot Tell Us Yet

Identifying variant frequency differences is not the same as demonstrating clinical impact. As PharmGKB has noted, most incretin-pathway pharmacogenomic associations carry a level-3 (low) evidence rating, meaning they come from single studies without replication [9]. Moving from allele frequency to dosing guidance requires prospective pharmacogenomic-stratified trials that simply have not been conducted for retatrutide.

Metabolic Context: Why Response Could Differ

Beyond receptor genetics, several physiologic and metabolic differences between Black and White populations could plausibly modify response to a triple agonist.

Insulin Resistance Patterns

Black Americans demonstrate higher insulin resistance and hyperinsulinemia at any given BMI compared to White Americans, a pattern documented across multiple NHANES cycles [10]. The GIPR agonist component of retatrutide acts partly through insulin-dependent mechanisms. Whether higher baseline insulin resistance blunts or amplifies the GIP-mediated effect is unknown. In the tirzepatide SURPASS-4 trial (a dual GIP/GLP-1 agonist), post hoc data showed numerically similar HbA1c reductions across racial subgroups, though the Black subgroup was small [11].

Body Composition Differences

DXA-based studies show that Black adults tend to carry less visceral adipose tissue and more lean mass at matched BMI values compared with White adults [12]. Retatrutide's glucagon component is expected to preferentially target hepatic and visceral fat through increased energy expenditure and lipid oxidation. If Black patients have proportionally less visceral fat at baseline, the glucagon-mediated metabolic benefit might differ in magnitude, though total weight loss could still be clinically significant.

Cardiorenal Comorbidity Burden

The intersection of obesity with hypertension and CKD is sharper in Black populations. Approximately 56% of Black adults in the U.S. Have hypertension, versus 48% of White adults [13]. CKD prevalence is also higher, driven in part by APOL1 risk variants carried by 10-15% of African Americans [14]. Retatrutide's Phase 2 data showed reductions in systolic blood pressure (approximately 5-10 mmHg across dose groups) [1]. Whether these cardiometabolic benefits are preserved, diminished, or amplified in Black patients with higher baseline cardiovascular risk requires dedicated study.

Dosing Considerations for Black Patients

No race-specific dosing adjustments exist for retatrutide. The Phase 2 protocol used a standardized titration schedule: 2 mg weekly for 4 weeks, escalating to 4, 8, or 12 mg depending on the randomized group [1].

Current Titration Protocol

All patients, regardless of race, followed the same escalation schedule. GI tolerability (nausea, vomiting, diarrhea) was the primary dose-limiting factor, occurring in 30-50% of participants on higher doses [1]. No race-stratified tolerability data were reported.

Why Empiric Dose Adjustment Is Premature

Some clinicians may be tempted to adjust dosing based on body weight or metabolic phenotype. This approach lacks evidence. Weight-based dosing was not used in any retatrutide arm, and the flat-dose design produced consistent percentage weight loss across BMI strata [1]. Until pharmacokinetic studies in diverse populations are published, the standard titration schedule should be followed regardless of ancestry.

Monitoring Recommendations

Given the absence of population-specific data, clinicians should apply standard monitoring with extra attention to parameters where disparities exist. HbA1c, fasting glucose, lipid panels, renal function (eGFR using the 2021 CKD-EPI creatinine equation, which removed the race coefficient) [15], and blood pressure should be tracked at baseline, 4 weeks, 12 weeks, and every 12 weeks thereafter.

The Phase 3 TRIUMPH Program: Will Diversity Improve?

Eli Lilly's Phase 3 TRIUMPH program includes multiple trials: TRIUMPH-1 through TRIUMPH-4, covering obesity with and without type 2 diabetes, as well as cardiovascular outcomes. Public listings on ClinicalTrials.gov indicate recruitment targets that span North America, Europe, Asia, and Latin America [16].

FDA Diversity Action Plans

Under the 2022 FDORA (Food, Drug, and Cosmetic Act reauthorization), sponsors of Phase 3 trials are expected to submit Diversity Action Plans describing enrollment goals for underrepresented populations [2]. Eli Lilly has not publicly disclosed its specific TRIUMPH diversity targets, but FDORA creates regulatory pressure that did not exist during Phase 2.

What Adequate Enrollment Would Look Like

To detect a clinically meaningful difference in weight-loss efficacy between Black and non-Black participants (for instance, a 3-percentage-point gap in body-weight reduction), a subgroup of at least 200-300 Black participants per treatment arm would be needed, assuming 80% power and alpha of 0.05. Achieving this across the TRIUMPH program is feasible if enrollment reflects U.S. Obesity demographics.

Equity Gaps in Obesity Pharmacotherapy Access

Even when medications prove equally effective across racial groups, access disparities can create real-world efficacy gaps.

Insurance and Cost Barriers

GLP-1 receptor agonists already face coverage restrictions. A 2023 KFF analysis found that only 25% of Medicare Part D plans covered semaglutide for obesity [17]. Retatrutide's anticipated pricing has not been disclosed, but triple-agonist therapy is unlikely to be cheaper than existing options. Black adults in the U.S. Are more likely to be covered by Medicaid (which often excludes anti-obesity medications) or to be uninsured [18].

Clinical Trial Awareness

Recruitment of Black participants into obesity trials is hampered by historical mistrust, geographic distance from trial sites, and narrower inclusion criteria that disproportionately exclude patients with comorbidities more common in Black populations [19]. The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy explicitly recommends that clinicians discuss clinical trial participation with underrepresented patients [20].

Prescriber Bias

Data from a 2022 study in JAMA Network Open showed that Black patients were 35% less likely to receive a GLP-1RA prescription for obesity compared with White patients after adjusting for BMI, comorbidities, and insurance status [21]. If this pattern persists into the retatrutide era, disparities in prescribing will widen the effective gap between populations regardless of pharmacologic efficacy.

What Clinicians Should Do Now

The evidence gap for retatrutide in Black patients is real but should not be confused with evidence of reduced efficacy. No published data suggest the drug works less well in Black individuals. The problem is the absence of data, not the presence of negative findings.

Prescribe retatrutide to eligible Black patients using the same titration protocol and monitoring schedule applied to all patients. Document outcomes systematically. Report adverse events through MedWatch. Encourage patients to consider TRIUMPH enrollment if eligible and geographically accessible. Track eGFR using the race-neutral 2021 CKD-EPI equation [15], and monitor blood pressure closely given the higher baseline hypertension prevalence in this population [13].